Mabwell Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
1,325
- Stock Symbol
-
688062
- Investments
-
2
- Share Price
-
$3.04
- (As of Friday Closing)
Mabwell General Information
Description
Mabwell (Shanghai) Bioscience Co Ltd is engaged in the research and development, production and sales of therapeutic biological products.
Contact Information
Website
www.mabwell.comCorporate Office
- Building 3, Creative Park
- No. 576 Libing Road, Pudong New Area
- Shanghai
- China
Corporate Office
- Building 3, Creative Park
- No. 576 Libing Road, Pudong New Area
- Shanghai
- China
Mabwell Stock Performance
As of 13-Nov-2026, Mabwell’s stock price is $3.04. Its current market cap is $1.32B with 447M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.04 | $3.22 | $2.97 - $6.85 | $1.32B | 447M | 7.38M | -$0.37 |
Mabwell Financials Summary
As of 30-Sep-2026, Mabwell has a trailing 12-month revenue of $104M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,913,894 | 2,376,046 | 1,185,787 | 1,743,862 |
| Revenue | 104,139 | 92,127 | 27,842 | 18,069 |
| EBITDA | (137,132) | (91,150) | (120,674) | (139,156) |
| Net Income | (152,349) | (134,792) | (145,485) | (148,898) |
| Total Assets | 790,862 | 651,142 | 585,678 | 628,481 |
| Total Debt | 540,097 | 417,325 | 303,582 | 182,355 |
Mabwell Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mabwell Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Mabwell Patents
Mabwell Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026200885-A1 | Antibody targeting claudin-1, adc thereof and use thereof | Pending | 25-Mar-2025 | ||
| WO-2026200906-A1 | Cd3-targeting antibody and use thereof | Pending | 25-Mar-2025 | ||
| WO-2026200905-A1 | Α-synuclein-targeting antibody and use thereof | Pending | 25-Mar-2025 | ||
| WO-2026189383-A1 | Combination therapy of b7-h3-targeting antibody-drug conjugate and parp-1 inhibitor | Pending | 11-Mar-2025 | ||
| WO-2026145668-A1 | Use of anti-nectin-4 antibody-drug conjugate in treating cancer and method therefor | Pending | 03-Jan-2025 |
Mabwell Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Mabwell Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Mabwell Investments (2)
Mabwell’s most recent deal was a Early Stage VC with Kalexo Bio. The deal was made on 17-Sep-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Kalexo Bio | 17-Sep-2025 | Early Stage VC | Drug Discovery | ||
| Slanhealth | 26-Mar-2025 | Later Stage VC | Outcome Management (Healthcare) |
Mabwell ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Mabwell FAQs
-
When was Mabwell founded?
Mabwell was founded in 2017.
-
Where is Mabwell headquartered?
Mabwell is headquartered in Shanghai, China.
-
What is the size of Mabwell?
Mabwell has 1,325 total employees.
-
What industry is Mabwell in?
Mabwell’s primary industry is Biotechnology.
-
Is Mabwell a private or public company?
Mabwell is a Public company.
-
What is Mabwell’s stock symbol?
The ticker symbol for Mabwell is 688062.
-
What is the current stock price of Mabwell?
As of 13-Nov-2026 the stock price of Mabwell is $3.04.
-
What is the current market cap of Mabwell?
The current market capitalization of Mabwell is $1.32B.
-
What is Mabwell’s current revenue?
The trailing twelve month revenue for Mabwell is $104M.
-
What is Mabwell’s annual earnings per share (EPS)?
Mabwell’s EPS for 12 months was -$0.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
